Journal article
Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses
Journal of the National Comprehensive Cancer Network, Vol.8(8), pp.881-885
08/2010
DOI: 10.6004/jnccn.2010.0065
PMID: 20870634
Abstract
Dermatofibrosarcoma protuberans (DFSP) is an uncommon, low grade soft-tissue malignancy associated with a high risk for local recurrence and widespread subclinical extension. Imatinib, a selective tyrosine kinase inhibitor, has been a beneficial adjuvant therapy in patients with unresectable, recurrent, or metastatic DFSP. Because of its characteristic infiltrative growth, effective surgical excision of DFSP may be limited by the risk for disfigurement or functional impairment. In recent cases, neoadjuvant imatinib mesylate therapy has been shown to reduce preoperative tumor size and lessen surgical morbidity associated with the removal of residual DFSP. Use of neoadjuvant imatinib before surgery, however, requires appropriate patient selection and careful weighing of the potential risks and benefits of this treatment.
Details
- Title: Subtitle
- Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses
- Creators
- Hillary Johnson-Jahangir - Department of Dermatology, Columbia University Medical Center, New York, New York 10032, USA. hj2256@columbia.eduWilliam ShermanDésirée Ratner
- Resource Type
- Journal article
- Publication Details
- Journal of the National Comprehensive Cancer Network, Vol.8(8), pp.881-885
- DOI
- 10.6004/jnccn.2010.0065
- PMID
- 20870634
- NLM abbreviation
- J Natl Compr Canc Netw
- ISSN
- 1540-1405
- eISSN
- 1540-1413
- Publisher
- United States
- Language
- English
- Date published
- 08/2010
- Academic Unit
- Dermatology
- Record Identifier
- 9984025319702771
Metrics
18 Record Views